• Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision

Overview

Questions and answers on Etopophos and associated names (etoposide, 100 and 1000 mg powder for solution for infusion)

Outcome of a procedure under Article 30 of Directive 2001/83/EC

On 21 April 2017, the European Medicines Agency completed a review of Etopophos. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Etopophos and associated names in the European Union (EU).

Etopophos is a cancer medicine used to treat: testicular cancer, lung cancer, ovarian cancer, gestational trophoblastic neoplasia (a rare tumour of the womb that occurs during pregnancy) and cancers of the blood (Hodgkin's and non-Hodgkin's lymphoma and acute myeloid leukaemia).

Etopophos contains the active substance etoposide (as etoposide phosphate) and is available as a powder to be made into a solution for infusion into a vein.

Etopophos is marketed in the following EU member States: France, Germany, Sweden and the United Kingdom. It is also available in the EU under the trade name Etopofos.

The company that markets these medicines is Bristol-Myers Squibb.

Etopophos is authorised in the EU via national procedures. This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.

Etopophos was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh).

On 14 October 2015, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Etopophos in the EU.

The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs and package leaflets should be harmonised across the EU.

The areas of the SmPC harmonised include:

4.1 Therapeutic indications

The CHMP recommended that Etopophos should be used in combination with other cancer treatments to treat the following cancers:

  • testicular cancer, including cancer that is resistant to treatment or has come back;
  • small-cell lung cancer;
  • Hodgkin's and non-Hodgkin's lymphoma;
  • acute myeloid leukaemia;
  • high-risk gestational trophoblastic neoplasia as first- and second-line treatments;
  • non-epithelial ovarian cancer.

In addition, the CHMP recommended Etopophos for treating epithelial ovarian cancer that is resistant to treatments with platinum-containing medicines, with no specification that it should be used in combination with other medicines.

For blood cancers (Hodgkin's and non-Hodgkin's lymphoma and acute myeloid leukaemia), Etopophos is recommended for both adults and children, while its other uses are for adults only.

4.2 Posology and method of administration

Etopophos is given as a slow intravenous infusion. The recommended dose for adults is 50 to 100 mg per m2 of body surface area for 5 days in a row or 100 to 120 mg/m2 on days 1, 3 and 5. The course of treatment may be repeated but not sooner than 21 days after the start of the first course.

4.3 Contra-indications

Etopophos should not be administered during vaccination with yellow fever or other live vaccines in patients with weakened immune systems and should not be given to breast-feeding women.

Other changes

Other sections of the SmPC harmonised include section 4.4 (special warnings and precautions), section 4.6 (fertility, pregnancy and lactation) and section 4.8 (undesirable effects).

български (BG) (107.44 KB - PDF)

View

español (ES) (81.38 KB - PDF)

View

čeština (CS) (104.68 KB - PDF)

View

dansk (DA) (81.28 KB - PDF)

View

Deutsch (DE) (83.98 KB - PDF)

View

eesti keel (ET) (80.81 KB - PDF)

View

ελληνικά (EL) (109.97 KB - PDF)

View

français (FR) (82.73 KB - PDF)

View

hrvatski (HR) (100.39 KB - PDF)

View

italiano (IT) (81.34 KB - PDF)

View

latviešu valoda (LV) (103.51 KB - PDF)

View

lietuvių kalba (LT) (103.14 KB - PDF)

View

magyar (HU) (95.55 KB - PDF)

View

Malti (MT) (124.56 KB - PDF)

View

Nederlands (NL) (81.48 KB - PDF)

View

polski (PL) (102.18 KB - PDF)

View

português (PT) (90.09 KB - PDF)

View

română (RO) (99.2 KB - PDF)

View

slovenčina (SK) (104.72 KB - PDF)

View

slovenščina (SL) (100.83 KB - PDF)

View

Suomi (FI) (81.64 KB - PDF)

View

svenska (SV) (81.66 KB - PDF)

View

Key facts

About this medicine

Approved name
Etopophos
International non-proprietary name (INN) or common name
etoposide phosphate

About this procedure

Current status
European Commission final decision
Reference number
EMEA/H/A-30/1417
Type
Article 30 referrals

This type of referral is triggered when Member States have adopted different decisions over the years for some medicines (e.g. different indications, contraindications or posology) and there is a need to harmonise across the EU.

Key dates and outcomes

CHMP opinion date
21/04/2017
EC decision date
26/06/2017

All documents

Opinion provided by Committee for Medicinal Products for human Use

български (BG) (393.61 KB - PDF)

View

español (ES) (215.71 KB - PDF)

View

čeština (CS) (346.4 KB - PDF)

View

dansk (DA) (208.76 KB - PDF)

View

Deutsch (DE) (233.74 KB - PDF)

View

eesti keel (ET) (218.81 KB - PDF)

View

ελληνικά (EL) (408.17 KB - PDF)

View

français (FR) (234.7 KB - PDF)

View

hrvatski (HR) (337.1 KB - PDF)

View

italiano (IT) (235.45 KB - PDF)

View

latviešu valoda (LV) (368.9 KB - PDF)

View

lietuvių kalba (LT) (367.24 KB - PDF)

View

magyar (HU) (340.54 KB - PDF)

View

Malti (MT) (383.61 KB - PDF)

View

Nederlands (NL) (221.23 KB - PDF)

View

polski (PL) (376.16 KB - PDF)

View

português (PT) (224.57 KB - PDF)

View

română (RO) (386.35 KB - PDF)

View

slovenčina (SK) (361.88 KB - PDF)

View

slovenščina (SL) (328.13 KB - PDF)

View

Suomi (FI) (212.25 KB - PDF)

View

svenska (SV) (236.53 KB - PDF)

View

български (BG) (107.44 KB - PDF)

View

español (ES) (81.38 KB - PDF)

View

čeština (CS) (104.68 KB - PDF)

View

dansk (DA) (81.28 KB - PDF)

View

Deutsch (DE) (83.98 KB - PDF)

View

eesti keel (ET) (80.81 KB - PDF)

View

ελληνικά (EL) (109.97 KB - PDF)

View

français (FR) (82.73 KB - PDF)

View

hrvatski (HR) (100.39 KB - PDF)

View

italiano (IT) (81.34 KB - PDF)

View

latviešu valoda (LV) (103.51 KB - PDF)

View

lietuvių kalba (LT) (103.14 KB - PDF)

View

magyar (HU) (95.55 KB - PDF)

View

Malti (MT) (124.56 KB - PDF)

View

Nederlands (NL) (81.48 KB - PDF)

View

polski (PL) (102.18 KB - PDF)

View

português (PT) (90.09 KB - PDF)

View

română (RO) (99.2 KB - PDF)

View

slovenčina (SK) (104.72 KB - PDF)

View

slovenščina (SL) (100.83 KB - PDF)

View

Suomi (FI) (81.64 KB - PDF)

View

svenska (SV) (81.66 KB - PDF)

View

European Commission final decision

български (BG) (53.34 KB - PDF)

View

español (ES) (19.79 KB - PDF)

View

čeština (CS) (45.87 KB - PDF)

View

dansk (DA) (18.89 KB - PDF)

View

Deutsch (DE) (19.56 KB - PDF)

View

eesti keel (ET) (19.08 KB - PDF)

View

ελληνικά (EL) (56.2 KB - PDF)

View

français (FR) (19.31 KB - PDF)

View

hrvatski (HR) (44 KB - PDF)

View

italiano (IT) (17.54 KB - PDF)

View

latviešu valoda (LV) (45.39 KB - PDF)

View

lietuvių kalba (LT) (47.91 KB - PDF)

View

magyar (HU) (19.94 KB - PDF)

View

Malti (MT) (46.45 KB - PDF)

View

Nederlands (NL) (19.15 KB - PDF)

View

polski (PL) (46.68 KB - PDF)

View

português (PT) (18.59 KB - PDF)

View

română (RO) (46.3 KB - PDF)

View

slovenčina (SK) (45.35 KB - PDF)

View

slovenščina (SL) (42.56 KB - PDF)

View

Suomi (FI) (19.18 KB - PDF)

View

svenska (SV) (19.29 KB - PDF)

View

български (BG) (69.74 KB - PDF)

View

español (ES) (50.37 KB - PDF)

View

čeština (CS) (81.83 KB - PDF)

View

dansk (DA) (49.06 KB - PDF)

View

Deutsch (DE) (52.2 KB - PDF)

View

eesti keel (ET) (49.34 KB - PDF)

View

ελληνικά (EL) (96.3 KB - PDF)

View

français (FR) (50.86 KB - PDF)

View

hrvatski (HR) (77.47 KB - PDF)

View

italiano (IT) (33.42 KB - PDF)

View

latviešu valoda (LV) (63.85 KB - PDF)

View

lietuvių kalba (LT) (81.48 KB - PDF)

View

magyar (HU) (54.47 KB - PDF)

View

Malti (MT) (82.94 KB - PDF)

View

Nederlands (NL) (35.03 KB - PDF)

View

polski (PL) (71.23 KB - PDF)

View

português (PT) (50.26 KB - PDF)

View

română (RO) (79.03 KB - PDF)

View

slovenčina (SK) (59.05 KB - PDF)

View

slovenščina (SL) (75.79 KB - PDF)

View

Suomi (FI) (48.75 KB - PDF)

View

svenska (SV) (49.97 KB - PDF)

View

Description of documents published

Please note that some of the listed documents apply only to certain procedures.

  • Overview - lay-language summary of the stage of the procedure
  • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
  • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
  • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
  • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
  • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
  • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
  • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
  • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
  • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
  • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
  • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
  • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
  • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
  • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

Note that older documents may have different titles.

Topics

How useful do you find this page?